Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in Ourense – page 4

76 clinical trials in Ourense, Spain. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Ourense at a glance
76
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

76 trials in Ourense

Open in trial search

Antithrombin III deficiency

Recruiting

Study on the Effectiveness of Atenativ for Patients with Congenital Antithrombin Deficiency Undergoing Surgery or Childbirth

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Antithrombin Iii Human
  • Sponsor:Octapharma AG

Bladder transitional cell carcinoma

Not yet recruiting

Phase 3 Study of Enfortumab Vedotin plus Pembrolizumab in Adults with Muscle‑Invasive Bladder Cancer Ineligible for Cystectomy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Enfortumab Vedotin
  • Sponsor:Pfizer Inc.

Study of setidegrasib (ASP3082) and docetaxel in patients with KRAS G12D‑mutated advanced/metastatic NSCLC after platinum chemo and checkpoint inhibitor

Not yet recruiting
Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:ASP3082
  • Sponsor:Astellas Pharma Global Development Inc.

Clear cell renal cell carcinoma

Not yet recruiting

A study of pembrolizumab, belzutifan, and lenvatinib before main treatment in patients with localized kidney cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Belzutifan
  • Sponsor:Vall D Hebron Institute Of Oncology

Gastric cancer+1

Not recruiting

Study on the Effectiveness and Safety of AZD0901 Compared to Standard Treatments for Adults with Advanced Gastric or Gastroesophageal Junction Cancer Expressing Claudin 18.2

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:AZD0901
  • Sponsor:AstraZeneca AB

Gastric cancer+1

Not recruiting

Study on Durvalumab and FLOT Chemotherapy for Patients with Resectable Gastric and Gastroesophageal Cancer

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:AstraZeneca AB

Colorectal cancer metastatic

Not recruiting

Phase III Study Comparing FOLFOX Plus Panitumumab Followed by FOLFIRI Plus Bevacizumab Versus FOLFOX Plus Bevacizumab Followed by FOLFIRI Plus Panitumumab in Wild-Type RAS Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Asociacion Grupo Tratamiento De Tumores Digestivos

Colorectal cancer metastatic

Not recruiting

A Study Comparing Telisotuzumab Adizutecan to Trifluridine, Tipiracil, and Bevacizumab in Adults with Refractory Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Hormone-refractory prostate cancer

Not recruiting

Study Comparing BMS-986365 with Other Treatments for Patients with Metastatic Castration-resistant Prostate Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Celgene Corp.

Oesophageal adenocarcinoma

Not recruiting

Study on ABBV-400, Fluorouracil, Leucovorin, and Budigalimab for Advanced or Metastatic Stomach and Esophageal Cancer Patients

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Budigalimab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Septic shock

Not recruiting

Study on Resuscitation in Early Septic Shock Using Sodium Chloride and a Drug Combination for Patients with Septic Shock

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Potassium Chloride
  • Sponsor:Pontificia Universidad Catolica de Chile

Embolism venous

Not recruiting

Study Comparing Abelacimab and Apixaban for Preventing Blood Clots in Cancer Patients

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Abelacimab
  • Sponsor:Anthos Therapeutics Inc.

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Ourense

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on advanced cancer treatments across multiple types, including prostate, lung, and gastrointestinal cancers. Studies evaluate novel therapeutic combinations and targeted approaches.

  • Metastatic Prostate Cancer Studies
  • Non-Small Cell Lung Cancer Trials
  • Gastrointestinal Cancer Research

Emphasis on personalized medicine approaches and immunotherapy combinations.

02 Hematological Studies

Research investigating treatments for various blood disorders and cancers, including multiple myeloma and lymphomas. Focus on targeted therapies and novel drug combinations.

  • Follicular Lymphoma Treatments
  • Myelodysplastic Syndrome Therapy
  • Chronic Lymphocytic Leukemia Research

Evaluating next-generation treatments for blood-related cancers.

03 Critical Care Medicine

Studies addressing urgent medical conditions including septic shock and respiratory infections. Research focuses on improving patient outcomes through innovative treatment protocols.

  • Sepsis Management Strategies
  • Respiratory Tract Infections
  • Emergency Care Protocols

Development of enhanced treatment approaches for critical conditions.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.